Reply to "no robust evidence of lumefantrine resistance"

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5867-5868

  Plucinski, Mateusz M ^a   Talundzic, Eldin ^a   Morton, Lindsay ^a   Dimbu, Pedro Rafael ^b   Macaia, Aleixo Panzo ^b   Fortes, Filomeno ^b   Goldman, Ira ^a   Lucchi, Naomi ^a   Stennies, Gail ^a   MacArthur, John R ^a   Udhayakumar, Venkatachalam ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Ministry of Health   (Angola)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; BENFLUMETOL; ARTEMISININ DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; QUINOLINE DERIVATIVE;

ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; DRUG EFFICACY; EVIDENCE BASED PRACTICE; GENE; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; MALARIA; MALARIA CONTROL; MEDICATION COMPLIANCE; NOTE; PFMDR1 GENE; PRACTICE GUIDELINE; PRIORITY JOURNAL; DRUG EFFECTS; FEMALE; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM;

ARTEMISININS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; QUINOLINES;

EID: 84940940656     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01355-15     Document Type: Note

References (10)

1. Hamed K, Kuhen K. 2015. No robust evidence of lumefantrine resistance. Antimicrob Agents Chemother 59:5865-5866. http://dx.doi.org/10.1128/AAC.00329-15.
2. Plucinski MM, Talundzic E, Morton L, Dimbu PR, Macaia AP, Fortes F, Goldman I, Lucchi N, Stennies G, MacArthur JR. 2015. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, Angola. Antimicrob Agents Chemother 59:437-443. http://dx.doi.org/10 .1128/AAC.04181-14.
3. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J. 2005. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 365:1467-1473. http://dx.doi.org/10.1016/S0140-6736(05)66416-1.
4. Borrmann S, Sallas WM, Machevo S, González R, Björkman A, Martensson A, Hamel M, Juma E, Peshu J, Ogutu B. 2010. The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 15:434-441. http://dx.doi.org/10.1111/j.1365-3156.2010.02477.x.
5. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. 2002. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2:209-218. http://dx.doi.org/10.1016/S1473-3099(02)00239-6.
6. Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Björkman A, Martensson A, Gil JP. 2013. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its associa-tion with pfmdr1 polymorphisms. J Infect Dis 207:842-847. http://dx.doi .org/10.1093/infdis/jis747.
7. Stepniewska K, White NJ. 2006. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J 5:127. http://dx.doi.org/10.1186/1475-2875-5-127.
8. Slater M, Kiggundu M, Dokomajilar C, Kamya MR, Bakyaita N, Talisuna A, Rosenthal PJ, Dorsey G. 2005. Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. Am J Trop Med Hyg 73:256-262.
9. Juliano JJ, Gadalla N, Sutherland CJ, Meshnick SR. 2010. The perils of PCR: can we accurately 'correct' antimalarial trials? Trends Parasitol 26: 119-124. http://dx.doi.org/10.1016/j.pt.2009.12.007.
10. Hastings IM, Ward SA. 2005. Coartem (artemether-lumefantrine) in Africa: the beginning of the end? J Infect Dis 192:1303-1304. http://dx.doi .org/10.1086/432554.